束敏峰 - 复旦大学 - 基础医学院

个人简介

教育经历 2001.09—2006.09 皖南医学院临床医学专业本科生 2006.09—2011.07 中山大学中山医学院药理学专业博士研究生工作经历 2011.10—2017.10 美国芝加哥大学博士后研究员 2017.11—至今复旦大学基础医学院青年研究员科研项目 2018，国家自然科学基金面上项目，“ATF3对恶性胶质瘤放疗敏感性的作用及机制”，主持 2019，上海市卫健委临床专项面上项目（项目编号：201940233），主持 2020，国家自然科学基金面上项目，“DNMT1在cAMP激动剂诱导胶质瘤定向分化中的作用及机制”，主持

研究领域

RNA稳态在恶性肿瘤发生发展和天然免疫中的作用研究基于病毒载体的肿瘤基因治疗药物研发

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Minfeng Shu, Te Du, Guoying Zhou and Bernard Roizman. The role of Activating Transcription Factor 3 in the synthesis of LAT and maintenance of HSV-1 in latent state in ganglia. Proc Natl Acad Sci U S A. 112(39): E5420-6 (2015). Minfeng Shu, Brunella Taddeo and Bernard Roizman. Tristetraprolin recruits the herpes simplex virion host shutoff RNase to the A-U rich elements in stress response mRNAs to enable their cleavage. Journal of Virology 89(10):5643-50 (2015) Minfeng Shu, Brunella Taddeo, Weiran Zhang and Bernard Roizman. Selective degradation of mRNAs by the HSV host shutoff RNase is regulated by the UL47 tegument protein. Proc Natl Acad Sci U S A. 110(18): E1669-75 (2013) Minfeng Shu, Brunella Taddeo and Bernard Roizman. The nuclear-cytoplasmic shuttling of virion host shutoff RNase is enabled by pUL47 and an embedded nuclear export signal and defines the sites of degradation of AU-rich and stable cellular mRNAs. Journal of Virology, 87(24): 13569-78 (2013) Minfeng Shu, Yuehan Zhou, Wenbo Zhu, Haipeng Zhang, Sihan Wu, Jingkao Chen,and Guangmei Yan. MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway. Molecular Pharmacology 81(3): 292-8 (2012) Minfeng Shu, Xiaoke Zheng , Sihan Wu, Huimin Lu, Tiandong Leng, Wenbo Zhu, Yuehan Zhou, Yanqiu Ou, Xi Lin, Yuan Lin, Dong Xu, Yuxi Zhou and Guangmei Yan. Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells. Molecular Cancer 19;10:59 (2011) Qian Liu , Ruotong Tian , Panpan Yu and Minfeng Shu*. miR-221/222 suppression induced by activation of the cAMP/PKA/CREB1 pathway is required for cAMP-induced bidirectional differentiation of glioma cells. FEBS Letters. 2021 Nov;595(22):2829-2843. Ruotong Tian, Yimin Li, Qian Liu and Minfeng Shu*. Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients. Cancers (Basel). 2021 Apr 6;13(7):1730. Ruotong Tian, Yimin Li and Minfeng Shu*. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response. Frontiers in Immunology. 2022 Jan 6;12:797450. Rucheng Yan, Weiwei Dai, Ruixin Wu, Houbao Huang and Minfeng Shu*. Therapeutic targeting m6A-guided miR-146a-5p signaling contributes to the melittin-induced selective suppression of bladder cancer. Cancer Letters. 2022 May 28;534:215615.

学术兼职

2015-今担任Cancer Research ,Clinical Cancer Research, Oncogene等20种 SCI学术期刊审稿专家 2017-今 Frontiers in Pharmacology Editorial board member 2019-今《中国临床药理学与治疗学》编委